Immune Checkpoint‐Bioengineered Beta Cell Vaccine Reverses Early‐Onset Type 1 Diabetes-Reference-Cited by-同舟云学术

Immune Checkpoint‐Bioengineered Beta Cell Vaccine Reverses Early‐Onset Type 1 Diabetes

Published:2021-05-08 Issue:25 Volume:33 Page:2101253
ISSN:0935-9648
Container-title:Advanced Materials
language:en
Short-container-title:Adv. Mater.

Author:

Au Kin Man¹²^ORCID,Medik Yusra¹²,Ke Qi³⁴,Tisch Roland³⁴,Wang Andrew Z.¹²⁴

Affiliation:

1. Laboratory of Nano‐ and Translational Medicine Carolina Center for Cancer Nanotechnology Excellence Carolina Institute of Nanomedicine University of North Carolina at Chapel Hill Chapel Hill NC 27599 USA

2. Department of Radiation Oncology Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Chapel Hill NC 27599 USA

3. Department of Microbiology and Immunology School of Medicine University of North Carolina at Chapel Hill Chapel Hill NC 27599 USA

4. Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Chapel Hill NC 27599 USA

Funder

School of Medicine

University of North Carolina at Chapel Hill

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

University of North Carolina

Publisher

Wiley

Subject

Mechanical Engineering,Mechanics of Materials,General Materials Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/adma.202101253

Reference45 articles.

1. Type 1 diabetes

2. Type 1 Diabetes: Etiology, Immunology, and Therapeutic Strategies

3. Type 1 diabetes mellitus

4. PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint modulators in early clinical development for the treatment of type 1 diabetes;Expert Opinion on Investigational Drugs;2024-03-13

2. Bioorthogonal chemistry mediated cell engineering for advanced cell and cell-derived vesicle therapies: Principles, progresses, and remaining challenges;Chemical Engineering Journal;2024-01

3. An injectable subcutaneous colon-specific immune niche for the treatment of ulcerative colitis;Nature Biomedical Engineering;2023-12-04

4. An in situ dual-anchoring strategy for enhanced immobilization of PD-L1 to treat autoimmune diseases;Nature Communications;2023-10-31

5. An Injectable Subcutaneous Colon-Specific Immune Niche For The Treatment Of Ulcerative Colitis;2023-10-04